Application of melaleuca virens essential oil monomer in preparation of medicine for treating cervicitis

Abstract

The invention relates to application of a melaleuca virens essential oil monomer in preparation of a medicine for treating cervicitis. According to the present invention, the monomer with the clear drug effect is separated from the melaleuca virens essential oil, such that the significant effect is provided in the treatment of cervicitis, the problem of the indefinite action mechanism of the melaleuca virens essential oil in the treatment of cervicitis is solved, the drug effect is significantly superior to the commercially available cervical cancer treatment drug, and the broad application prospect is provided.

Description

Background technology:

[0001] Female reproductive tract infections have long been a challenging social and public health problem, with high incidence and recurrence rates and a wide range of impacts. Among the many reproductive tract infections, cervicitis is particularly prevalent. Clinically, patients with cervicitis often experience symptoms such as cervical edema, cervical bleeding, and abnormal vaginal discharge. In recent years, the incidence of cervicitis in my country has continued to rise, making the effective treatment of cervicitis a pressing challenge in the field of gynecological clinical practice.

[0002] The cervix serves as a critical barrier preventing pathogens from entering the upper reproductive tract from the lower genital tract. It also serves as a crucial pathway for sperm to enter the uterine cavity, menstrual blood to be discharged, and the fetus to be delivered. Its unique physiological location makes it extremely vulnerable to pathogenic invasion. Data show that approximately 36.9% of married women suffer from cervicitis. Furthermore, if untreated, cervicitis can lead to complications such as endometritis, salpingitis, and chronic pelvic pain, and is a significant risk factor for cervical cancer. Studies have shown that women with cervicitis have a 4.4 to 7 times higher risk of cervical cancer than the general population.

[0003] Modern medicine primarily treats cervicitis with antibiotics and symptomatic treatment. However, improper and long-term use of antibiotics has led to a growing problem of drug resistance, significantly compromising treatment effectiveness. Furthermore, the safety and effectiveness of Western medicine alone remain controversial, prompting Traditional Chinese Medicine (TCM) treatments to become a research hotspot.

[0004] Numerous clinical trials and long-term clinical practice have demonstrated the significant advantages of Traditional Chinese Medicine (TCM) in treating cervicitis, not only alleviating drug resistance but also reducing toxic side effects. However, existing TCM treatments for cervicitis, such as Funing Suppositories and Kushen Suppositories, suffer from poor efficacy and low cure rates, which not only reduce treatment efficiency but also may lead to other complications. Therefore, identifying more effective TCM ingredients for the treatment of cervicitis is a pressing task.

[0005] Niaouli (Melaleucaviridiflora Sol.ex Gaertn.) is a tree in the Myrtaceae family, the genus Melaleuca. It is mentioned in the Xinhua Compendium of Materia Medica and is found in Yunnan, Guangdong, and Guangxi provinces of my country. It is native to Australia. In traditional medicine, Niaouli is often used to dispel wind and dredge the meridians, relieve qi stagnation, relieve pain, and expel parasites. Modern research has revealed that Niaouli essential oil exhibits multiple pharmacological activities, including antibacterial, anti-inflammatory, anti-tumor, and antioxidant activities. However, the current efficacy of Niaouli essential oil in the treatment of cervicitis is unclear. This not only limits its extensive application in the treatment of cervicitis but also hinders its full clinical efficacy and scientific evaluation. Further analysis of the medicinal value of individual compounds in Niaouli and clarifying its specific mechanism of action in the treatment of cervicitis are crucial for the development of safer and more effective cervicitis treatments. This is expected to fill the current gap in cervicitis treatment and bring new hope to patients. Summary of the invention:

[0006] The present invention explores active ingredients in Niaouliu essential oil for treating cervicitis and relates to the use of Niaouliu essential oil monomers in the preparation of a medicament for treating cervicitis. The Niaouliu essential oil monomers include eucalyptol, 4-terpenol, or α-terpineol.

[0007] Specifically, the present invention relates to the use of Niaouliu essential oil monomers in the preparation of drugs for treating cervicitis, wherein the Niaouliu essential oil monomers are selected from one of eucalyptol, 4-terpenol, and α-terpineol.

[0008] In some embodiments, the Niaouliu truncatula essential oil monomer is the only active ingredient.

[0009] In some embodiments, the medicament includes a pharmaceutically acceptable excipient.

[0010] In some embodiments, the medicament is a tablet, capsule, injection, suppository, ointment, cream, or gel.

[0011] Beneficial effects

[0012] The present invention identifies the effective active ingredients of Niaouli essential oil for treating cervicitis, among which 4-terpenol is more effective than eucalyptol and α-terpineol, and is superior to the commercially available Baofukang suppository. This provides a single active ingredient with a clear structure and significant efficacy for the treatment of cervicitis. Description of the drawings:

[0013] Figure 1Pathological sections of rat cervix in different experimental groups: A. Normal group; B. Model group; C. Baofukang suppository group; D. Eucalyptol group; E. α-terpineol group; F. 4-terpene alcohol group; squamous epithelial cells showed deformation, shedding, or necrosis (blue arrows), and inflammatory cell infiltration (black arrows).

[0014] Figure 2 : Cervical pathological scores of rats in different experimental groups

[0015] Specific implementation cases

[0016] The following examples may enable those skilled in the art to more fully understand the present invention, but the present invention is not limited to the scope of the examples.

[0017] Example 1

[0018] 1.1 Experimental animals

[0019] Forty-eight non-pregnant female Sprague-Dawley rats (180-220 g, 6-8 weeks) were purchased from Hunan Slakejing Experimental Animal Co., Ltd. The experimental animals were housed in individually ventilated cages at the Animal Experimental Center of Dali University, with alternating dark and day cycles of 12 h, a controlled temperature of 16-22°C, and a humidity of 40%-60%. All animal experiments complied with the guidelines of the Chinese Laboratory Animal Research Ethics Committee, animal approval number: 2022-PZ-102, and animal license number: SCXK(Xiang)2019-0004.

[0020] 1.2 Experimental Reagents

[0021] Melaleuca alternifolia essential oil (batch number 20190623) was purchased from Yunnan Ouyi Biotechnology Co., Ltd.; sodium carboxymethyl cellulose (batch number F20110509) was purchased from Sinopharm Chemical Reagent Co., Ltd.; phenol (batch number 14100400) was purchased from Xilong Chemical Co., Ltd.; mono- and distearic fatty acid glycerides (batch number 141004) were purchased from Chengdu Lutianhua Kesen Co., Ltd.; 95% ethanol (batch number 131101) was purchased from Sichuan Jinshan Pharmaceutical Co., Ltd.; glycerol (batch number 20141230) was purchased from Zhejiang Suichang Huikang Pharmaceutical Co., Ltd.; eucalyptol (item number C14284170), 4-terpenol (item number C164458), and α-terpineol (item number A151628) were all purchased from Shanghai MacLean Biochemical Technology Co., Ltd., and mixed fatty acid glycerides (batch number: 141004) were purchased from Chengdu Lutianhua Kesen Co., Ltd.

[0022] 1.3 Test drugs

[0023] Melaleuca alternifolia monomer essential oil suppositories: Weigh mono- and distearic acid glycerides and mixed fatty acid glycerides in a ratio of 1:4, melt in a 60°C water bath, and add the active ingredients to prepare suppositories containing eucalyptol, 4-terpenol, and α-terpineol monomers (each suppository contains 2.75 mg, 0.98 mg, and 0.55 mg, respectively). Prepare 0.2 g / suppository for later use.

[0024] 1.4 Positive drugs

[0025] Baofukang Suppository (BFKS), specification is 1.74g / pill, the clinical prescription dosage for the treatment of cervicitis is 1 pill / time, 1 time / day, and the Baofukang Suppository group of rats was dosed with 1.413mg / 100g.

[0026] Preparation of Baofukang suppositories: Weigh mono- and distearic acid glycerides and mixed fatty acid glycerides in a ratio of 1:4, melt them in a 60°C water bath, stir and mix them evenly, take an appropriate amount of commercially available Baofukang suppositories and add them to make suppositories containing 3 mg of the main drug Baofukang suppository per pill for later use.

[0027] 1.5 Model drugs

[0028] In a 50°C water bath, accurately weigh 4 mL of liquid phenol, 1 g of sodium carboxymethyl cellulose, and 6 mL of glycerol and mix thoroughly. Dilute the mixture with 9 mL of distilled water and stir again to prepare a 20% phenol slurry. Seal the slurry and store it in a refrigerator at 4°C. All experiments were conducted at room temperature.

[0029] 1.6 Experimental Instruments

[0030] Precision electronic analytical balance; high pressure sterilizer; biological tissue slicer; desktop high-speed refrigerated centrifuge; biological tissue embedding machine; freezing table; microplate reader; automatic dehydrator; manual slicer; medical image analysis system, etc.

[0031] 1.7 Cervicitis modeling and scoring criteria

[0032] 1.7.1 Method for establishing phenol-induced cervicitis model in rats

[0033] A 20% phenol glue was used to establish the model. Female non-pregnant rats weighing 220-240 g were selected for the model. Six rats served as the normal control group, and the remaining 30 rats were used for the cervicitis model. Rats were anesthetized with isoflurane and then placed in the supine position and immobilized. A pre-sterilized 1.0 mL syringe was gently inserted into the rat's cervical fornix. Next, a 1.0 mL disposable syringe with a blunt gavage needle was gently inserted into the rat's cervical fornix. 20% phenol glue was slowly introduced into the cervix while the syringe was withdrawn at an appropriate speed. After the injection, the rats were tilted in a head-high, tail-low position for 5 minutes and then returned to their home cages. The model was established once every 3 days for the first 3 days, with 0.1 mL of phenol glue injected. Thereafter, the model was established once every 3 days with 0.2 mL of phenol glue injected for 3 consecutive times.

[0034] 1.7.2 Scoring criteria for inflammatory response in the phenol rat cervicitis model

[0035] With reference to the Methodology of Pharmacological Research of Traditional Chinese Medicine and based on the degree of inflammation in the Toxicity Test Method for Vaginal Preparations of Traditional Chinese Medicine, a scoring standard for vulvar inflammation in rats with phenol-induced cervicitis and a grading standard for vulvar inflammation in rats with phenol-induced cervicitis were developed (see Tables 1 and 2).

[0036] Table 1 Inflammatory response indexes of vulva in rats with cervicitis induced by phenol mucilage

[0037]

[0038]

[0039] Table 2 Grading criteria for vulvar inflammatory response in rats with phenol mucilage cervicitis

[0040]

[0041] 1.7.3 Animal grouping

[0042] Three days after the final modeling, the rats were visually observed for changes in vaginal inflammation. Based on the aforementioned "Vulvar Inflammation Scoring Criteria for Phenol-Induced Cervicitis in Rats," the rats were categorized into four levels: no inflammation, mild inflammation, moderate inflammation, and severe inflammation. The degree of vulvar inflammation in the rats was visually assessed by three members of the experimental group, and the average score was used to determine the severity of the model inflammation.

[0043] There were 6 rats in each of the three dosage groups: normal group, model group, Baofukang suppository group, and Niaouliu essential oil monomer suppository group.

[0044] 1.7.4 Method of administration

[0045] After the rats were grouped, the normal group received no special treatment, the model group was given normal saline at a dose of 0.05 mL / 100 g, and the other groups began to receive medication on the same day. The dosages were three monomer dose groups of Niaouliu Thunbergii essential oil (each suppository contained 2.75 mg of eucalyptol, 0.98 mg of 4-terpenol, and 0.55 mg of α-terpineol), and the Baofukang suppository group (1.413 mg / 100 g). All were administered vaginally, 1 tablet per day, for 7 consecutive days.

[0046] 1.7.5 Observation of general symptoms and vulvar inflammation scores in rats with cervicitis

[0047] During treatment, the rats were observed for general signs, including appearance, behavior, eating and drinking habits, and independent mobility, to identify any abnormalities. Furthermore, the vaginal and cervical regions of the rats were examined, and their appearance (including redness, edema, and discharge) was recorded and scored based on the observations. The rats were weighed, photographed, and recorded on days 1, 4, and 7 after treatment.

[0048] 1.7.6 Observation of Tissues and Organs in Rats with Cervicitis

[0049] (1) During the entire period of drug intervention, the survival status of the experimental group rats was closely monitored. During the dissection process, the organs of the rats were carefully examined and their size and color were recorded to see if they were abnormal. For organs with obvious pathological changes, samples were taken and further pathological analysis was performed. After blood was collected from the abdominal aorta of the rats, the rats were killed by dislocating the neck. The liver, spleen and cervical tissue (from the vaginal opening to the bifurcation of the uterus) of the rats were removed. During the operation, attached fat tissue and mesentery should be removed. Next, the organs were immersed in normal saline (NS) for 2 to 3 times, and the water adsorbed on the surface of the organs was absorbed with dust-free filter paper. They were weighed and their respective organ indexes were calculated according to the following formula.

[0050] Organ index = corresponding organ weight (mg) / rat weight before sacrifice (g)

[0051] (2) Observation of mortality and tissue status of rats with pelvic inflammatory disease during drug administration

[0052] During the treatment period, the death of rats in each group was observed. If any rat died, the time of death should be determined as accurately as possible and the rat should be dissected in time to observe whether the size and color of its tissues and organs were abnormal. Those with obvious lesions needed to be sampled for pathological histological observation. The relevant scoring and grading standards were referred to Table 3.

[0053] Table 3 Grading of rat uterine histopathological changes

[0054]

[0055] Table 4 Grading of histopathological changes in cervicitis rat model

[0056]

[0057] 1.7.7 Detection methods of relevant indicators in rats with cervicitis

[0058] (1) Determination of rat organ index

[0059] After the final dose, rats were fasted for 12 hours but not water. Rats were anesthetized with an intraperitoneal injection of 10% chloral hydrate, and blood was drawn from the abdominal aorta before being sacrificed. The uterus was dissected and removed, and surrounding adipose tissue and mesentery were removed. The uterus was then rinsed 2-3 times in normal saline, removed, dried with filter paper, and accurately weighed on an analytical balance. Organ index was calculated as follows: uterine weight (mg) / rat weight before sacrifice (g).

[0060] (2) Detection of biochemical indicators in uterine tissue of rats with cervicitis

[0061] The removed rat uterine tissue was divided from the middle, half of the uterine tissue was first quick-frozen in liquid nitrogen, and then stored at -80℃ to prepare a 10% tissue homogenate. The EGF, IL-6, IL-10, TNF-α, and IL-1β indicators in the uterine tissue of rats with cervicitis were determined.

[0062] 1.7.8 Histopathology Tests and Histopathology Scoring Criteria

[0063] Histopathology Testing Procedure

[0064] 1. Sample Collection and Fixation

[0065] Surgical resection, biopsy, or animal experiment sampling

[0066] Immediately fix with 10% neutral buffered formalin (24-48 hours)

[0067] 2. Dehydration and embedding

[0068] Gradient alcohol dehydration (70% → 80% → 95% → 100%)

[0069] Xylene transparent

[0070] Paraffin embedding (forming tissue wax blocks)

[0071] 3. Sectioning and Staining

[0072] Cut with a microtome to a thickness of 4-5 μm

[0073] Conventional HE staining (hematoxylin-eosin) to observe the basic structure

[0074] Special stains (such as Masson trichrome staining for fibrosis and PAS staining for glycogen)

[0075] 4. Microscope Observation and Scoring

[0076] Use a low-power microscope (40×-100×) to observe the overall structure

[0077] High magnification microscope (200×-400×) to observe cell details

[0078] Record the severity of the lesion according to the scoring criteria

[0079] 5. Data Analysis

[0080] Calculate the average pathological score of each group

[0081] Statistical methods (such as t-test, ANOVA) were used to compare the differences between groups.

[0082] Histopathological scoring is usually based on microscopic observations of tissue structural changes, inflammation, fibrosis, necrosis, cell atypia, and other characteristics. Common scoring methods include:

[0083] 1. Semi-quantitative scoring (e.g., 0-4 point scale)

[0084] 0 points: normal, no pathological changes

[0085] 1 point: slight changes (such as a small amount of inflammatory cell infiltration)

[0086] 2 points: moderate changes (such as local necrosis or fibrosis)

[0087] 3 points: significant changes (extensive inflammation or structural destruction)

[0088] 4 points: severe lesions (such as large areas of necrosis or cancer)

[0089] 2. Inflammation score (such as chronic inflammation score)

[0090] Lymphocytic infiltration (0: none; 1: mild; 2: moderate; 3: severe)

[0091] Neutrophil infiltration (same as above)

[0092] Granuloma formation (yes / no)

[0093] 3. Fibrosis score (such as liver, lung, and kidney fibrosis)

[0094] Grade 0: No fibrosis

[0095] Grade 1: Mild (focal fibrosis)

[0096] Grade 2: Moderate (fibrous septa formation)

[0097] Grade 3: Severe (extensive fibrosis or cirrhosis)

[0098] 4. Tumor grade (such as cancer pathological grade)

[0099] Degree of differentiation (high / moderate / low differentiation)

[0100] Nuclear atypia (mild / moderate / severe)

[0101] Mitotic index (low / medium / high)

[0102] The test results of the present invention are as follows:

[0103] 1. HE staining results are as follows Figure 1 As shown. The cervical mucosal tissue structure of the normal group was clear and complete, covered with keratinized squamous epithelium with normal morphology, rich collagen in the lamina propria, and tightly arranged; the epidermal layer of the cervical tissue mucosa of rats in the model group was blurred, the squamous epithelial cells were deformed, shed or necrotic (blue arrows), and the boundaries of the squamous columnar epithelial cells were unclear, and a large number of inflammatory cells were seen in the cervical stroma (black arrows); compared with the model group, the squamous columnar epithelial cells in the Baofukang suppository group were clearly demarcated, the squamous epithelium of the rat cervical mucosa showed hyperplasia and repair and slightly thickening, no deformed or necrotic squamous epithelial cells were seen, but there was still a small amount of inflammatory infiltration, and the inflammatory cells were scattered and few; the three monomer drug groups all showed varying degrees of improvement, among which 4-terpenol made the proliferation and repair of squamous epithelial cells in the cervical tissue mucosa of rats the most significant. Histopathological scores are as follows Figure 2 As shown in the results, medium and high doses of 4-terpenol improved the histopathological scores better than the commercially available drug Baofukang Suppository.

[0104] 2. The effects of different groups on the body weight of SD rats are shown in Table 5.

[0105] Normal group: The body weight remained stable without significant fluctuations, indicating that the experimental environment had no significant effect on normal rats.

[0106] Model group: The body weight on the 1st and 4th day was significantly lower than that of the normal group (*p<0.05), but was close to the normal level on the 7th day, suggesting that the initial stage of modeling may cause short-term stress to the animals, but gradually recovered in the later stage.

[0107] 4-Terpene alcohol dosage groups:

[0108] Low-dose group (L): Weight gain was slower and still significantly lower than that of the normal group on the 7th day. A higher dose may be needed to improve the effect.

[0109] Medium-dose group (M): Body weight returned to near normal levels on the 4th day, showing a good short-term recovery effect, but decreased slightly on the 7th day.

[0110] High-dose group (H): The body weight on the 7th day was significantly higher than that of the other intervention groups (270.3±9.5g), and even slightly higher than that of the normal group, indicating that high-dose 4-terpenol can effectively promote weight recovery without adverse reactions.

[0111] Baofukang suppository group: The body weight was always lower than that of the normal group, and the effect was not as good as the high-dose 4-terpenol group.

[0112] Table 5. Effects of different experimental groups on body weight changes in SD rats (n=6)

[0113]

[0114]

[0115] Compared with the Normal group * P﹤0.05, ** P﹤0.01; compared with the Model group # P﹤0.05, ## P﹤0.01; compared with Baofukang suppository group △ P﹤0.05, △△ P﹤0.01; compared with the low-dose group ▲ P﹤0.05, ▲▲ P﹤0.01; compared with the medium dose group ▽ P﹤0.05, ▽▽ P < 0.01

[0116] 3. The effects of different experimental groups on the cervical index are shown in Table 6. The cervical index (CI) generally refers to the ratio of cervical weight to body weight (mg / g) and is used to assess the severity of cervical inflammation or pathology. Evaluation criteria: Lower values ​​indicate milder cervical inflammation or edema, and closer to normal. Higher values ​​indicate more severe cervical inflammation or tissue pathology.

[0117] Normal group (Normal): The cervical index was the lowest (1.3±0.2 mg / g), serving as the healthy control benchmark.

[0118] Model group: The cervical index increased significantly (1.8±0.4 mg / g), indicating that the model was successfully established and the cervical inflammation was obvious.

[0119] Comparison of the effects of the intervention groups:

[0120] Baofukang Suppository group (BFKS): The cervical index (1.2±0.3 mg / g) was significantly lower than that of the model group, and even slightly better than that of the normal group, indicating a good anti-inflammatory effect.

[0121] 4-Terpene alcohol dosage groups:

[0122] The medium-dose group (0.425 mg / kg) performed best (1.2±0.2 mg / g), with no significant difference from the normal group, and was significantly better than the model group, and even better than the Baofukang Suppository (BFKS) group.

[0123] High-dose group (0.85 mg / kg): The cervical index (1.4±0.2 mg / g) was similar to that of the low-dose group, and no dose-escalation effect was shown, which may indicate that the optimal dose is in the medium-dose range.

[0124] Table 6. Effects of different experimental groups on cervical index (n=6)

[0125]

[0126] Compared with the Normal group * P﹤0.05, ** P﹤0.01; compared with the Model group # P﹤0.05, ## P﹤0.01; compared with Baofukang suppository group △ P﹤0.05, △△ P﹤0.01; compared with the low-dose group ▲ P﹤0.05, ▲▲ P﹤0.01; compared with the medium dose group ▽ P﹤0.05, ▽▽ P < 0.01

[0127] 4. The effects of different experimental groups on vulvar inflammation scores are shown in Table 7. The inflammation scores of all experimental groups on the 4th and 7th days were significantly lower than those of the model group, showing a good anti-inflammatory effect. Over time, the inflammation scores of each experimental group gradually decreased, showing a positive correlation between dose and effect. The inflammation score of the normal group was always 0, indicating that the experimental material had no effect on normal tissue. By comparing different groups, the anti-inflammatory effect of each experimental material can be more comprehensively evaluated. These data show that the experimental group has a significant advantage in reducing the inflammation score, especially on the 4th and 7th days, and the 4-terpene alcohol H group showed good anti-inflammatory potential.

[0128] Table 7. Effects of different experimental groups on vulvar inflammation scores (n=6)

[0129]

[0130] Compared with the Normal group * P﹤0.05, ** P﹤0.01; compared with the Model group # P﹤0.05, ## P﹤0.01; compared with Baofukang suppository group △P﹤0.05, △△ P﹤0.01; compared with the low-dose group ▲ P﹤0.05, ▲▲ P﹤0.01; compared with the medium dose group ▽ P﹤0.05, ▽▽ P < 0.01

[0131] 5. The effects of different experimental groups on IL-1β, IL-6, IL-10, EGF, TNF-α, and TGF-β in cervicitis rat tissues are shown in Table 8. All experimental groups (Baofukang Suppository group, 4-terpenol L group, 4-terpenol M group, and 4-terpenol H group) significantly reduced the levels of inflammatory factors (IL-1β, IL-6, IL-10, EGF, TNF-α, and TGF-β) at different time points, demonstrating a positive anti-inflammatory effect. Over time, inflammatory factor levels gradually decreased in each experimental group, demonstrating a positive correlation between dose and effect. Comparison of different groups allows for a more comprehensive assessment of the anti-inflammatory effects of each experimental material. Inflammatory factor levels in the normal group were consistently low, indicating that the experimental materials had no effect on normal tissues. These data demonstrate that the experimental groups had a significant advantage in reducing inflammatory factor levels, particularly on days 4 and 7, with 4-terpenol H demonstrating excellent anti-inflammatory potential.

[0132] Table 8. Effects of different experimental groups on IL-1β, IL-6, IL-10, EGF, TNF-α, and TGF-β in cervicitis rat tissues (n=6)

[0133]

[0134]

[0135] Compared with the Normal group * P﹤0.05, ** P﹤0.01; compared with the Model group # P﹤0.05, ## P﹤0.01; compared with Baofukang suppository group △ P﹤0.05, △△ P﹤0.01; compared with the low-dose group ▲ P﹤0.05, ▲▲ P﹤0.01; compared with the medium dose group ▽ P﹤0.05, ▽▽ P﹤0.01.

[0136] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.

Claims

1. Application of Niaouliu Thunbergii essential oil monomer in the preparation of a drug for treating cervicitis, wherein the Niaouliu Thunbergii essential oil monomer is selected from one of eucalyptol, 4-terpenol, and α-terpineol.

2. The use according to claim 1, wherein The Niaouliu essential oil monomer serves as the only active ingredient.

3. The use according to any one of claims 1 to 2, wherein the medicament comprises a pharmaceutically acceptable excipient.

4. The use according to any one of claims 1 to 3, wherein the pharmaceutical dosage form is a tablet, capsule, injection, suppository, ointment, cream or gel. The use according to claim 4 , wherein the pharmaceutical dosage form is a suppository.

6. The use according to claim 5, wherein the suppository is prepared by weighing mono- and distearic glyceryl and mixed fatty acid glycerides in a ratio of 1:4, melting them in a 60°C water bath, and then adding the active ingredient to prepare a suppository containing three monomers: eucalyptol, 4-terpenol, or α-terpineol.

Images